Company

Newleos Therapeutics, Inc.

Newleos Therapeutics develops drug candidates for neuropsychiatric conditions.

About

Newleos is developing therapies for anxiety, social anxiety, substance use disorders, and cognitive impairment. Its pipeline includes NTX-1955, NTX-1472, NTX-2001, and NTX-1511. Based in Massachusetts, US, the company was founded by Longwood, Christoph Westphal, Miguel Sobral, and Rob Hadfield. In February 2025, it raised USD 93.5 million in Series A funding led by Goldman Sachs Asset Management, with Novo Holdings, Longwood Fund, Data Collective, and Arkin Bio Capital participating.

1Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in